223 related articles for article (PubMed ID: 11190237)
21. Introduction: antibiotic short-course therapy---where are the limits?
Finch RG
J Int Med Res; 2000; 28 Suppl 1():1A-2A. PubMed ID: 11092224
[No Abstract] [Full Text] [Related]
22. [Clinical and laboratory problems related to the application of antibiotics].
Xiao YH
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):357-9. PubMed ID: 15559879
[No Abstract] [Full Text] [Related]
23. [The diagnostic basis for a rational antibacterial therapy].
Lystad A
Tidsskr Nor Laegeforen; 1968 Feb; 88(4):277-81. PubMed ID: 4876489
[No Abstract] [Full Text] [Related]
24. [Environment and development of epidemics].
Mayr A
Fortschr Med; 1972 Apr; 90(10):355-6, 398. PubMed ID: 4681729
[No Abstract] [Full Text] [Related]
25. Tuberculosis and the human immunodeficiency virus: unholy marriage of the millennium.
Chakaya JM
East Afr Med J; 2008 Nov; 85(11):521-2. PubMed ID: 19413203
[No Abstract] [Full Text] [Related]
26. Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance.
Colgan R; Powers JH
Am Fam Physician; 2001 Sep; 64(6):999-1004. PubMed ID: 11578036
[TBL] [Abstract][Full Text] [Related]
27. Key pathogens and emerging therapies in infectious diseases.
Miller PF; Mueller JP
Curr Opin Pharmacol; 2009 Oct; 9(5):535-6. PubMed ID: 19766536
[No Abstract] [Full Text] [Related]
28. Infectious diseases.
Stoeckle MY; Douglas RG
JAMA; 1993 Jul; 270(2):223-4. PubMed ID: 8315739
[No Abstract] [Full Text] [Related]
29. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis.
Nathan C; Gold B; Lin G; Stegman M; de Carvalho LP; Vandal O; Venugopal A; Bryk R
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S25-33. PubMed ID: 18762150
[TBL] [Abstract][Full Text] [Related]
30. Controlling antimicrobial resistance. An integrated action plan for Canadians.
Health Canada and The Canadian Infectious Disease Society
Can Commun Dis Rep; 1997 Nov; 23 Suppl 7():i-iv, 1-32, i-iv, 1-32. PubMed ID: 11195276
[No Abstract] [Full Text] [Related]
31. Using host defenses to fight infectious diseases.
Kelley KJ
Nat Biotechnol; 1996 May; 14(5):587-90. PubMed ID: 9630947
[No Abstract] [Full Text] [Related]
32. Avoiding the challenges of emerging infectious disease and antibiotic resistance.
Molinari JA
J Mass Dent Soc; 2000; 49(3):8-9, 51. PubMed ID: 11323859
[No Abstract] [Full Text] [Related]
33. Importance of integrons in the diffusion of resistance.
Carattoli A
Vet Res; 2001; 32(3-4):243-59. PubMed ID: 11432416
[TBL] [Abstract][Full Text] [Related]
34. Emergent antibiotic resistance: health risks and economic impact.
Cassell GH
FEMS Immunol Med Microbiol; 1997 Aug; 18(4):271-4. PubMed ID: 9348162
[No Abstract] [Full Text] [Related]
35. [Infectious diseases-Part II: New agents, resistances, and treatment strategies].
Salzberger B; Franzen C; Glück T
Med Klin (Munich); 2004 May; 99(5):251-60. PubMed ID: 15146288
[TBL] [Abstract][Full Text] [Related]
36. Infectious diseases and antibiotic resistance in long-term care facilities.
Bonomo RA
Postgrad Med; 2001 Feb; 109(2 Suppl):70-7. PubMed ID: 19667560
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
[No Abstract] [Full Text] [Related]
38. [Editorial: Chemotherapy of infectious diseases, 1974].
Ther Umsch; 1974 Jun; 31(6):365-8. PubMed ID: 4467347
[No Abstract] [Full Text] [Related]
39. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
Johnson VA; Petropoulos CJ; Woods CR; Hazelwood JD; Parkin NT; Hamilton CD; Fiscus SA
J Infect Dis; 2001 Jun; 183(11):1688-93. PubMed ID: 11343221
[TBL] [Abstract][Full Text] [Related]
40. [The worldwide challenges of "new" or reemerging communicable diseases at the dawn of the 21st century].
Werner GH
Ann Pharm Fr; 2001 Jul; 59(4):246-77. PubMed ID: 11468579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
